Sugi Predict

Sugi Predict / Compounds / SCHEMBL1645481

SCHEMBL1645481

SCHEMBL1645481

CCOC(=O)Cc1ccc(OC)c(Oc2ccc(NS(=O)(=O)c3ccc(Cl)cc3)cc2CN2CCOC2=O)c1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 3/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ PPARG P37231 1/20 0.40
▸ PTGDR Q13258 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ HIF1A Q16665 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ ALPL P05186 2/20 0.39
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1644669 0.91 PTGDR2 (0.48) PTGDR2PTGDR
SCHEMBL1643733 0.87 LMNA (0.41) ALDH1A1KDM4ELMNAHSD17B10KMT2A
SCHEMBL1643664 0.87 CPT1A (0.44) PTGDR2ALDH1A1LMNATSHRHSD17B10
SCHEMBL1643912 0.83 L3MBTL1 (0.44) PTGDR2ALDH1A1KDM4ELMNAKMT2A
SCHEMBL1644798 0.82 CYP3A4 (0.51) PTGDR2ALDH1A1KDM4ELMNAKMT2A
SCHEMBL1643702 0.82 L3MBTL1 (0.51) PTGDR2ALDH1A1KDM4ELMNAHSD17B10
SCHEMBL1644646 0.82 LMNA (0.38) ALDH1A1LMNAKMT2AMAPT
SCHEMBL1643253 0.81 L3MBTL1 (0.46) PTGDR2ALDH1A1KDM4ELMNATSHR
SCHEMBL1644732 0.81 LMNA (0.41) ALDH1A1KDM4ELMNAKMT2AMAPT
SCHEMBL1643553 0.81 ALDH1A1 (0.42) ALDH1A1KDM4ELMNATSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242145-B2 Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-14 — — US disclosed
US-8242145-B2 Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-14 — — US disclosed
US-8242145-B2 Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-14 — — US disclosed
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-28 — — US disclosed
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-28 — — US disclosed
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-28 — — US disclosed
WO-2009102893-A2 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors AMIRA PHARMACEUTICALS, INC. (US) 2009-08-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER1 PTGDR2 2/4885ALDH1A1 2220/4885KDM4E 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.